| Title |
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
|
|---|---|
| Published in |
OncoTargets and therapy, November 2021
|
| DOI | 10.2147/ott.s325208 |
| Pubmed ID | |
| Authors |
Mª Del Carmen Álamo, Sebastian Ochenduszko, Guillermo Crespo, Mónica Corral, Juana Oramas, Pilar Sancho, Javier Medina, Fernando Garicano, Pedro López, Begoña Campos Balea, Analia Rodríguez Garzotto, Eva Muñoz-Couselo |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 25% |
| Spain | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 19% |
| Librarian | 2 | 13% |
| Student > Bachelor | 2 | 13% |
| Student > Ph. D. Student | 2 | 13% |
| Student > Master | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 5 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 19% |
| Medicine and Dentistry | 3 | 19% |
| Computer Science | 1 | 6% |
| Philosophy | 1 | 6% |
| Chemistry | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 6 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2022.
All research outputs
#15,751,285
of 25,392,582 outputs
Outputs from OncoTargets and therapy
#840
of 3,016 outputs
Outputs of similar age
#223,152
of 443,559 outputs
Outputs of similar age from OncoTargets and therapy
#4
of 42 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,559 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.